These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 32698715)

  • 1. Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?D. Deniffel, E. Salinas, M. Ientilucci, A. J. Evans, N. Fleshner, S. Ghai, R. Hamilton, A. Roberts, A. Toi, T. van der Kwast, A. Zlotta, A. Finelli, M. A. Haider and N. Perlis
    Stavrinides V; Giganti F; Punwani S; Allen C; Kirkham A; Freeman A; Ball R; Haider A; Whitaker H; Orczyk C; Emberton M; Moore CM
    J Urol; 2020 Nov; 204(5):1065-1066. PubMed ID: 32698715
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance: F. Zhao, E. Olkhov-Mitsel, T. van der Kwast, J. Sykes, D. Zdravic, V. Venkateswaran, A. R. Zlotta, A. Loblaw, N. E. Fleshner, L. Klotz, D. Vesprini and B. Bapat J Urol 2017;197:335-341.
    Zhao F; Jeyapala R; Olkhov-Mitsel E; Vesprini D; Fleshner NE; Bapat B
    J Urol; 2018 May; 199(5):1354-1355. PubMed ID: 29428633
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer. N. Lawrentschuk, A. Finelli, T. H. Van der Kwast, P. Ryan, D. M. Bolton, N. E. Fleshner, J. Trachtenberg, L. Klotz, M. Robinette and H. Woo. J Urol 2011;185: 862-868.
    Dickinson L; Ahmed HU; Emberton M
    J Urol; 2011 Sep; 186(3):1159-60; author reply 1160-1. PubMed ID: 21784489
    [No Abstract]   [Full Text] [Related]  

  • 4. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
    J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Utility of 4Kscore
    de la Calle CM; Fasulo V; Cowan JE; Lonergan PE; Maggi M; Gadzinski AJ; Yeung RA; Saita A; Cooperberg MR; Shinohara K; Carroll PR; Nguyen HG
    J Urol; 2021 Feb; 205(2):452-460. PubMed ID: 32897802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary on "randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients." Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M, Laszlo S, Hersey K, Klotz L, Finelli A, Fleshner N, Vieth R, Department of Nutritional Sciences, University of Toronto, Ontario, Canada.: J Clin Endocrinol Metab 2013;98(4):1498-507 [Epub 2013 Mar 5].
    Olumi AF
    Urol Oncol; 2014 Feb; 32(2):210. PubMed ID: 24445291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate BiopsiesA. Amin, M. J. Scheltema, R. Shnier, A. Blazevski, D. Moses, T. Cusick, A. Siriwardena, B. Yuen, P. J. van Leeuwen, A. M. Haynes, J. Matthews, P. Brenner, G. O'Neill, C. Yuen, W. Delprado, P. Stricker and J. Thompson
    Montorsi F; Gandaglia G; Fossati N; Briganti A
    J Urol; 2020 Oct; 204(4):843. PubMed ID: 32609573
    [No Abstract]   [Full Text] [Related]  

  • 8. Hydroids (Cnidaria, Hydrozoa) from Mauritanian Coral Mounds.
    Gil M; Ramil F; AgÍs JA
    Zootaxa; 2020 Nov; 4878(3):zootaxa.4878.3.2. PubMed ID: 33311142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. T. Wolters, M. J. Roobol, P. J. van Leeuwen, R. C. van den Bergh, R. F. Hoedemaeker, G. J. van Leenders, F. H. Schröder and T. H. van der Kwast. J Urol 2011;185: 121-125.
    Moore CM; Klotz L; Emberton M
    J Urol; 2011 Sep; 186(3):1158-9; author reply 1159. PubMed ID: 21784490
    [No Abstract]   [Full Text] [Related]  

  • 10. RE: A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank SpecimensD. T. S. Woon, J. O. Herrera-Cáceres, H. Goldberg, H. Shiakh, E. Whelan, G. Nason, K. Ajib, G. Hee Tan, T. Chandrasekar, O. Alhunaidi, A. Finelli, A. Zlotta, A. Berlin, E. Diamantis and N. Fleshner
    Rahman SN; Flores VX; Monaghan TF; Weiss JP
    J Urol; 2021 Jan; 205(1):276-277. PubMed ID: 33035145
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis.
    Goldberg H; Ahmad AE; Chandrasekar T; Klotz L; Emberton M; Haider MA; Taneja SS; Arora K; Fleshner N; Finelli A; Perlis N; Tyson MD; Klaassen Z; Wallis CJD
    J Urol; 2020 Jun; 203(6):1085-1093. PubMed ID: 31609177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility.
    Shoag JE; Tosoian JJ; Salami SS; Barbieri CE
    Eur Urol; 2019 Jul; 76(1):24-26. PubMed ID: 30712974
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of magnetic resonance image guided prostate biopsy in stratifying men for risk of extracapsular extension at radical prostatectomy. Raskolnikov D, George AK, Rais-Bahrami S, Turkbey B, Siddiqui MM, Shakir NA, Okoro C, Rothwax JT, Walton-Diaz A, Sankineni S, Su D, Stamatakis L, Merino MJ, Choyke PL, Wood BJ, Pinto PA. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland; e-mail: pintop@mail.nih.gov.J Urol. 2015 Jul;194(1):105-11. [Epub 2015 Jan 23]. doi: 10.1016/j.juro.2015.01.072.
    Scott E
    Urol Oncol; 2017 Mar; 35(3):121. PubMed ID: 28159491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank SpecimensDixon T. S. Woon, Jaime O. Herrera-Cáceres, Hanan Goldberg, Hina Shiakh, Emily Whelan, Gregory Nason, Khaled Ajib, Guan Hee Tan, Thenappan Chandrasekar, Omar Alhunaidi, Antonio Finelli, Alexandre Zlotta, Alejandro Berlin, Eleftherios Diamantis and Neil Fleshner
    Li N; Sun Y; Li JG; Long H
    J Urol; 2021 Jan; 205(1):277. PubMed ID: 33035146
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Utility of Multiparametric Magnetic Resonance Imaging in the Risk Stratification of Men with Grade Group 1 Prostate Cancer on Active Surveillance.
    Taneja SS
    J Urol; 2020 Aug; 204(2):386. PubMed ID: 32401653
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Giorgio Gandaglia, Guillaume Ploussard, Massimo Valerio, et al. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. Eur Urol 2020;77:733-41.
    Aning J; McCoubrie P; Oxley J
    Eur Urol; 2020 Nov; 78(5):e198-e199. PubMed ID: 32839000
    [No Abstract]   [Full Text] [Related]  

  • 17. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.
    Recabal P; Assel M; Sjoberg DD; Lee D; Laudone VP; Touijer K; Eastham JA; Vargas HA; Coleman J; Ehdaie B
    J Urol; 2016 Aug; 196(2):374-81. PubMed ID: 26920465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stock.
    Norris JM; Simpson BS; Parry MA; Kasivisvanathan V; Allen C; Ball R; Freeman A; Kelly D; Kirkham A; Whitaker HC; Emberton M
    BJU Int; 2020 Mar; 125(3):340-342. PubMed ID: 31600865
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostate Mapping for Cancer Diagnosis: The Madrid Protocol. Transperineal Prostate Biopsies Using Multiparametric Magnetic Resonance Imaging Fusion and Micro-Ultrasound Guided Biopsies.
    Rodríguez Socarrás ME; Gomez Rivas J; Cuadros Rivera V; Reinoso Elbers J; Llanes González L; Michel Mercado I; Fernandez Del Alamo J; Juarez Del Dago P; Sancha FG
    J Urol; 2020 Oct; 204(4):726-733. PubMed ID: 32314932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy: A. R. Rastinehad, B. Turkbey, S. S. Salami, O. Yaskiv, A. K. George, M. Fakhoury, K. Beecher, M. A. Vira, L. R. Kavoussi, D. N. Siegel, R. Villani and E. Ben-Levi. J Urol 2014; 191: 1749-1754.
    Patodia M; Goel A; Kumar M
    J Urol; 2014 Dec; 192(6):1888; discussion 1888-9. PubMed ID: 25194541
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.